newsfilter
← Latest News
GlobeNewswire·

Structure Therapeutics Reports Third Quarter 2024 Financial Results and Recent Highlights

First patients dosed in Phase 2b ACCESS study of GSBR-1290 for obesity Oral small molecule amylin receptor agonist development candidate expected to be selected by the end of 2024 Strong financial position with cash,